《2035年目标——私营部门贡献情况更新》
Target 2035 - an update on private sector contributions.
作者信息
Ackloo Suzanne, Antolin Albert A, Bartolome Jose Manuel, Beck Hartmut, Bullock Alex, Betz Ulrich A K, Böttcher Jark, Brown Peter J, Chaturvedi Menorca, Crisp Alisa, Daniels Danette, Dreher Jan, Edfeldt Kristina, Edwards Aled M, Egner Ursula, Elkins Jon, Fischer Christian, Glendorf Tine, Goldberg Steven, Hartung Ingo V, Hillisch Alexander, Homan Evert, Knapp Stefan, Köster Markus, Krämer Oliver, Llaveria Josep, Lessel Uta, Lindemann Sven, Linderoth Lars, Matsui Hisanori, Michel Maurice, Montel Florian, Mueller-Fahrnow Anke, Müller Susanne, Owen Dafydd R, Saikatendu Kumar Singh, Santhakumar Vijayaratnam, Sanderson Wendy, Scholten Cora, Schapira Matthieu, Sharma Sujata, Shireman Brock, Sundström Michael, Todd Matthew H, Tredup Claudia, Venable Jennifer, Willson Timothy M, Arrowsmith Cheryl H
机构信息
Structural Genomics Consortium, University of Toronto Toronto Ontario M5G 1L7 Canada
ProCURE, Catalan Institute of Oncology, Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL) L'Hospitalet del Llobregat Barcelona Catalonia Spain
出版信息
RSC Med Chem. 2023 Mar 16;14(6):1002-1011. doi: 10.1039/d2md00441k. eCollection 2023 Jun 22.
Target 2035, an international federation of biomedical scientists from the public and private sectors, is leveraging 'open' principles to develop a pharmacological tool for every human protein. These tools are important reagents for scientists studying human health and disease and will facilitate the development of new medicines. It is therefore not surprising that pharmaceutical companies are joining Target 2035, contributing both knowledge and reagents to study novel proteins. Here, we present a brief progress update on Target 2035 and highlight some of industry's contributions.
“2035目标”是一个由公共和私营部门生物医学科学家组成的国际联盟，它正在利用“开放”原则为每一种人类蛋白质开发一种药理学工具。这些工具对于研究人类健康和疾病的科学家来说是重要的试剂，将促进新药的开发。因此，制药公司加入“2035目标”，为研究新型蛋白质贡献知识和试剂也就不足为奇了。在这里，我们简要介绍一下“2035目标”的进展情况，并重点介绍一些行业贡献。
Zotero 插件